Press Releases
Debiopharm progresses in their stand against drug-resistant N. gonorrhoeae with extended CARB-X funding of their Debio 1453 antibiotic program
A pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor (ICI)-resistant disease by…
Debiopharm’s novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients
Debiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients
Debiopharm and BIOASTER join forces to expand research to combat infectious diseases
Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel…
Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial
Debiopharm awarded $2.1 million from CARB-X in the fight against a highly resistant nosocomial-pneumonia causing superbug